Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...5455565758596061626364...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial initiation date, Surgery, Bariatric surgery:  Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery (clinicaltrials.gov) -  Sep 2, 2020   
    P4,  N=36, Recruiting, 
    Extended retroperitoneal resection with vascular reconstruction may be an option for local control in selected isolated late recurrence of slow growing gynecologic tumors. Initiation date: Mar 2020 --> Aug 2020
  • ||||||||||  Journal:  Radiopharmaceuticals for Treatment of Osteosarcoma. (Pubmed Central) -  Sep 1, 2020   
    Accurate knowledge of oligometastatic active disease can facilitate more effective use of combination therapy, including radiosensitizers and local control measures, for example, stereotactic body radiotherapy (SBRT) and/or cryoablation to reduce disease burden as well as manage and prevent micrometastatic disease from growing and metastasizing. Finally, a new tumor-specific radiopharmaceutical, CLR 131, may also provide another radiopharmaceutical to treat both osteoblastic and non-ossifying areas of osteosarcoma.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Off-label uses of denosumab in metabolic bone diseases. (Pubmed Central) -  Aug 30, 2020   
    Moreover, Dmab was administered to improve hypercalcemia induced by various diseases, including primary hyperparathyroidism, tuberculosis and immobilization. The aim of this review is to summarize existing evidence on off-label uses of Dmab in metabolic bone diseases and provide opinion for or against its use, which should be always considered on an individual basis.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Denosumab-induced hypocalcaemia in metastatic gastric cancer. (Pubmed Central) -  Aug 30, 2020   
    We present a case of a hospice inpatient with profound and recurring hypocalcaemia following a single denosumab infusion which required repeated hospitalisation, for intravenous calcium, alongside a prolonged course of vitamin D and electrolyte replacement. The case highlights the risk of hypocalcaemia with denosumab use, together with the need to identify and treat vitamin D deficiency in both the prevention and management of such a complication.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Treatment of osteoporosis in dialysis patients Experience with anti-RANKL antibody denosumab () -  Aug 30, 2020 - Abstract #JSN2020JSN_936;    
    (Femur neck 0.40 ± 0.12 before administration, 1 year after administration 0.45 ± 0.14 g/cm2) (Lumbar vertebra administration 0.81 ± 0.19, 1 year after administration 0.84 ± 0.16 g/cm2) Post-administration and decrease in serum calcium level Although iPTH level increased, it could be prevented by adjusting the dose of calcium carbonate before administration of denosumab. [Discussion/Conclusion] Denosumab is useful for treating osteoporosis in dialysis patients.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Effect of denosumab on osteoporosis in maintenance dialysis patients () -  Aug 30, 2020 - Abstract #JSN2020JSN_300;    
    Lumbar spine YAM values ​​before and after administration of denosumab were 88.2 ± 17 → 91.3 ± 17 (%), and femoral neck YAM values ​​were 63.0 ± 6.2 → 63.1 ± 6.2 (%). As for bone metabolism markers, BAP was 15.0 ± 5.8 → 10.1 ± 4.1 (μg/L), P1NP was 234 ± 93 → 168 ± 100 (μg/L), TRCP-5b was 514 ± 180 → 292 ± 220, all significantly decreased.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. (Pubmed Central) -  Aug 28, 2020   
    The case in point has been the development of Denosumab, a RANKL-blocking monoclonal antibody which has already helped millions of patients suffering from post-menopausal osteoporosis and skeletal related events in cancer. Here we will provide an overview of the pathway from its origins to its clinical relevance in disease, with a special focus on emerging evidence demonstrating the therapeutic value of targeting the RANKL/RANK/OPG axis not only in breast cancer but also as an addition to the cancer immunotherapy arsenal.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, risedronate / Generic mfg., zoledronic acid / Generic mfg.
    Retrospective data, Journal:  Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. (Pubmed Central) -  Aug 27, 2020   
    Here we will provide an overview of the pathway from its origins to its clinical relevance in disease, with a special focus on emerging evidence demonstrating the therapeutic value of targeting the RANKL/RANK/OPG axis not only in breast cancer but also as an addition to the cancer immunotherapy arsenal. To sum up, abaloparatide, denosumab, and teriparatide showed the best efficacy for the treatment of postmenopausal osteoporosis, especially abaloparatide.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion, Trial completion date, Trial primary completion date:  Presurgical Trial of Denosumab in Breast Cancer (clinicaltrials.gov) -  Aug 21, 2020   
    P1,  N=44, Completed, 
    A limitation is that safety outcomes failed to consider the severity of adverse effects. Recruiting --> Completed | Trial completion date: Jun 2020 --> Jan 2020 | Trial primary completion date: Jun 2020 --> Dec 2019
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
    Clinical, Review, Journal:  Osteoporosis in Older Adults. (Pubmed Central) -  Aug 20, 2020   
    Bisphosphonates are a first-line therapy for many patients with osteoporosis. Other treatments for osteoporosis include denosumab, teriparatide, abaloparatide, romosozumab, and selective estrogen receptor modulators.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    [VIRTUAL] Evidence-Based project and Quality Initiative towards improving decision making and outcomes in Prostate Cancer bone health at Salt Lake City VA () -  Aug 19, 2020 - Abstract #AVAHO2020AVAHO_36;    
    When evaluating the effect of the decision tool on the desiredoutcomes, we note that the fraction of patients getting overly intensive treatment before and afterimplementation of the tool was 24/41 vs 0/10 (p = 0.0008); lack of pretreatment dental assessment beforeand after implementation of the tool was noted to be 12/41 vs 0/10): (p =0.09). Fisher’s Exact Test wasused for both comparisons.Implications: Through implementation of an evidence-based algorithm and clinical practice tool whileprescribing bone remodeling agents to patients with prostate cancer, we were able to improve ourinstitutional practice to a high quality evidenced-based approach to prostate cancer bone health care.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Osteogenesis imperfecta-pathophysiology and therapeutic options. (Pubmed Central) -  Aug 17, 2020   
    Timely remobilization and regular strengthening of the muscles by physiotherapy are crucial to improve mobility, prevent muscle wasting and avoid bone resorption caused by immobilization. Identification of the pathomechanism for SERPINF1 mutations led to the development of a tailored mechanism-based therapy using denosumab, and unraveling further pathomechanisms will likely open new avenues for innovative treatment approaches.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
    [VIRTUAL] Osteoporosis: An Overview (Feed 1) -  Aug 16, 2020 - Abstract #ACRARHP2020ACR_ARHP_501;    
    Identification of the pathomechanism for SERPINF1 mutations led to the development of a tailored mechanism-based therapy using denosumab, and unraveling further pathomechanisms will likely open new avenues for innovative treatment approaches. Learning Objectives: Present a review of current data on osteoporosis treatments, including anabolic therapy, denosumab and "drug holidays" Describe the mechanism of action and use of romosozumab Discuss regimens of combination and sequential osteoporosis treatments Discuss the presentations of hypophosphatasia in rheumatology practice, including diagnosis and management
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial initiation date:  Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) -  Aug 12, 2020   
    P4,  N=45, Not yet recruiting, 
    Learning Objectives: Present a review of current data on osteoporosis treatments, including anabolic therapy, denosumab and "drug holidays" Describe the mechanism of action and use of romosozumab Discuss regimens of combination and sequential osteoporosis treatments Discuss the presentations of hypophosphatasia in rheumatology practice, including diagnosis and management Initiation date: Jun 2020 --> Oct 2020
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion, Trial completion date, Metastases:  SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) -  Aug 11, 2020   
    P3,  N=514, Completed, 
    Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Oct 2022 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Feb 2020
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion:  Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=61, Completed, 
    Four months later the case was resolved by means of non-surgical treatment. Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion date, Trial primary completion date:  Denosumab for the Treatment of Adult LCH (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=12, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Feb 2021 --> May 2021
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
    Review, Journal:  Multiple Myeloma Associated Bone Disease. (Pubmed Central) -  Aug 6, 2020   
    Bisphosphonates have, for many years, played a key role in management of MBD, but denosumab is now an alternative to bisphosphonates, especially in patients with renal impairment...Cement augmentation has been shown to reduce pain from vertebral compression fractures. Cautious exercise programs are safe and feasible and may have the potential to improve the status of patients with MM.